Refractory vaccine-induced immune thrombotic thrombocytopenia (VITT) managed with delayed therapeutic plasma exchange (TPE).
coronavirus
platelet factor
thrombocytopenia
thrombosis
vaccines
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
revised:
08
10
2021
received:
25
07
2021
accepted:
09
10
2021
pubmed:
22
10
2021
medline:
9
2
2022
entrez:
21
10
2021
Statut:
ppublish
Résumé
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a newly described hematologic disorder, which presents as acute thrombocytopenia and thrombosis after administration of the ChAdOx1 nCov-19 (AstraZeneca) and Ad26.COV2.S (Johnson & Johnson) adenovirus-based vaccines against COVID-19. Due to positive assays for antibodies against platelet factor 4 (PF4), VITT is managed similarly to autoimmune heparin-induced thrombocytopenia (HIT) with intravenous immunoglobulin (IVIG) and non-heparin anticoagulation. We describe a case of VITT in a 50-year-old man with antecedent alcoholic cirrhosis who presented with platelets of 7 × 10
Substances chimiques
Ad26COVS1
JT2NS6183B
PF4 protein, human
0
Platelet Factor 4
37270-94-3
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-121Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(23):2202-2211. doi:10.1056/NEJMoa2105385
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092-2101. doi:10.1056/NEJMoa2104840
Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124-2130. doi:10.1056/NEJMoa2104882
Muir K-L, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021;384(20):1964-1965. doi:10.1056/NEJMc2105869
See I, Su JR, Lale A, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. 2021;325(24):2448. doi:10.1001/jama.2021.7517
Sangli S, Virani A, Cheronis N, et al. Thrombosis with thrombocytopenia after the messenger RNA-1273 vaccine. Ann Intern Med. 2021;174(10):1480-1482. doi:10.7326/L21-0244
Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021. doi:10.1056/nejmoa2109908
Nazy I, Sachs UJ, Arnold DM, et al. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC subcommittee on platelet immunology. J Thromb Haemost. 2021;19(6):1585-1588. doi:10.1111/jth.15341
International Society on Thrombosis and Haemostasis (ISTH). The ISTH Releases Interim Guidance on Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). International Society on Thrombosis and Haemostasis. 2021 [cited 2021Jul1]. Available from: https://www.isth.org/news/561406/The-ISTH-Releases-Interim-Guidance-on-Vaccine-Induced-Immune-Thrombotic-Thrombocytopenia-VITT-.htm.
British Society for Haematology. Guidance produced by the Expert Haematology Panel (EHP) focused on Vaccine Induced Thrombosis and Thrombocytopenia (VITT). British Society for Haematology. 2021 [cited 2021Jul1]. Available from: https://b-s-h.org.uk/about-us/news/guidance-produced-by-the-expert-haematology-panel-ehp-focussed-on-vaccine-induced-thrombosis-and-thrombocytopenia-vitt/.
Irani M, Siegal E, Jella A, Aster R, Padmanabhan A. Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia. Transfusion. 2018;59(3):931-934. doi:10.1111/trf.15105
Bourguignon A, Arnold DM, Warkentin TE, et al. Adjunct immune globulin for vaccine-induced IMMUNE thrombotic thrombocytopenia. N Engl J Med. 2021;385(8):720-728. doi:10.1056/nejmoa2107051
Onuoha C, Barton KD, Wong ECC, et al. Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin-induced thrombocytopenia: a systematic review. Transfusion. 2020;60(11):2714-2736. doi:10.1111/trf.16018
Oldenburg J, Klamroth R, Langer F, et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie. 2021;41:184-189. doi:10.1055/a-1469-7481
Favaloro EJ. Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol. 2021 Aug;43(4):559-570. doi:10.1111/ijlh.13629
Patriquin CJ, Laroche V, Selby R, et al. Therapeutic plasma exchange in vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;385(9):857-859. doi:10.1056/nejmc2109465
Rock G, Weber V, Stegmayr B. Therapeutic plasma exchange (TPE) as a plausible rescue therapy in severe vaccine-induced immune thrombotic thrombocytopenia. Transfus Apher Sci. 2021;60(4):103174. doi:10.1016/j.transci.2021.103174
Al-Mayhani T, Saber S, Stubbs MJ, et al. Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. J Neurol Neurosurg Psychiatry. 2021;92(11):1247-1248. doi:10.1136/jnnp-2021-326984